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Abstract
AIM: To investigate the diagnostic performance of 
acoustic radiation force impulse (ARFI) elastography 
for characterizing focal liver mass by quantifying their 
stiffness.
METHODS: This prospective study included 62 pa-
tients with a focal liver mass that was well visualized 
on conventional ultrasonography performed in our 
institution from February 2011 to November 2011. 
Among them, 12 patients were excluded for ARFI mea-
surement failure due to a lesion that was smaller than 
the region of the interest and at an inaccessible loca-
tion (deeper than 8 cm) (n  = 7) or poor compliance 
to hold their breath as required (n  = 5). Finally, 50 
patients with valid ARFI measurements were enrolled. 
If a patient had multiple liver masses, only one mass 
of interest was chosen. The masses were diagnosed by 
histological examination or clinical diagnostic criteria. 
During ultrasonographic evaluation, stiffness, expressed 
as velocity, was checked 10 times per focal liver mass 
and the surrounding liver parenchyma.
RESULTS: After further excluding three masses that 
were non-diagnostic on biopsy, a total of 47 focal mass 
lesions were tested, including 39 (83.0%) malignant 
masses [24 hepatocellular carcinomas (HCC), seven 
cholangiocellular carcinomas (CCC), and eight liver 
metastases] and eight (17.0%) benign masses (five 
hemangiomas and three focal nodular hyperplasias, 
FNH). Thirty-seven (74.0%) masses were confirmed by 
histological examination. The mean velocity was 2.48 
m/s in HCCs, 1.65 m/s in CCCs, 2.35 m/s in metasta-
ses, 1.83 m/s in hemangiomas, and 0.97 m/s in FNHs. 
Although considerable overlap was still noted between 
malignant and benign masses, significant differences 
in ARFI values were observed between malignant and 
benign masses (mean 2.31 m/s vs  1.51 m/s, P  = 0.047), 
as well as between HCCs and benign masses (mean 2.48 
m/s vs  1.51 m/s, P  = 0.006). The areas under the re-
ceiver operating characteristics curves (AUROC) for dis-
criminating the malignant masses from benign masses 
was 0.724 (95%CI, 0.566-0.883, P  = 0.048), and the 
AUROC for discriminating HCCs from benign masses 
was 0.813 (95%CI, 0.649-0.976, P  = 0.008). To maxi-
mize the sum of sensitivity and specificity, an ARFI value 
of 1.82 m/s was selected as the cutoff value to differen-
tiate malignant from benign liver masses. Furthermore, 
the cutoff value for distinguishing HCCs from benign 
masses was also determined to be 1.82 m/s. The diag-
nostic performance of the sum of the ARFI values for 
focal liver masses and the surrounding liver parenchyma 
to differentiate liver masses improved (AUROC = 0.853; 
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95%CI, 0.745-0.960; P  = 0.002 in malignant liver 
masses vs  benign ones and AUROC = 0.948; 95%CI, 
0.896-0.992, P  < 0.001 in HCCs vs  benign masses).
CONCLUSION: ARFI elastography provides additional 
information for the differential diagnosis of liver mass-
es. However, our results should be interpreted in clinical 
context, because considerable overlap in ARFI values 
existed among liver masses.
© 2013 Baishideng. All rights reserved.
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INTRODUCTION
Focal liver masses are being discovered at increasing rates 
due to the wide accessibility of  modern high resolution 
imaging procedures. Conventional ultrasonography (US) 
is typically used as a first imaging modality to evaluate a 
focal liver mass. The differential diagnosis of  a focal liver 
mass using imaging studies is based on the characteris-
tics of  the surrounding liver parenchyma and underlying 
clinical conditions such as cirrhosis and the characteris-
tics of  the mass itself. Although contrast-enhanced US, 
computed tomography (CT), and magnetic resonance 
imaging (MRI) can assess the morphology of  a focal liver 
mass and its vasculature with a high level of  diagnostic 
accuracy[1-5], patients are exposed to potential risks, in-
cluding contrast medium-induced side-effects and irradia-
tion hazards[6], particularly when repeated examinations 
are required.
Acoustic radiation force impulse (ARFI) elastogra-
phy has been introduced as a new ultrasound imaging 
modality to evaluate tissue stiffness using the radiation 
forced-based imaging method. The tissue response to the 
radiation force is observed using conventional B-mode 
imaging pulses, and it is possible to display the quantita-
tive shear wave velocity (m/s) of  the ARFI image[7,8]. 
Because velocity is directly related to tissue stiffness, 
ARFI imaging can be applied to evaluate tissue elasticity. 
Generally, the stiffer the tissue, the faster the shear wave 
propagates[6,9-13]. Although several reports have indicated 
a good correlation of  ARFI elastography with the other 
elastography systems such as transient elastography[14,15] 
and with histological fibrosis grade[14,16,17], ARFI elastog-
raphy differs from other elastography systems which ap-
ply pressure manually to the surface of  the organs or a 
mechanical vibration to induce an elastic shear wave with 
only M-mode US imaging. Instead, ARFI uses short-du-
ration acoustic pulses generated from a probe under real-
time B-mode imaging to produce localized displacements 
in tissue[18-20]. Furthermore, because ARFI elastography 
uses elastography with a flexible metering box of  the 
region of  the interest (ROI), it is the only elastography 
method suitable for quantifying focal liver mass stiffness.
Few reports have investigated the applicability of  
ARFI elastography to evaluate focal liver masses[6,20-25]. 
Thus, we prospectively recruited patients with a focal 
liver mass and investigated the diagnostic performance of  
ARFI elastography to discriminate malignant liver masses 
and hepatocellular carcinoma (HCC) from benign masses 
by quantifying their stiffness.
MATERIALS AND METHODS
Subjects
From February 2011 to November 2011, a total of  62 
patients with a focal liver mass that was well visualized 
on conventional US were prospectively recruited for this 
study. The subjects were referred to our institute for fur-
ther evaluation of  a focal liver mass from primary or sec-
ondary clinics, or had been diagnosed with a focal liver 
mass during a surveillance examination at our institute. 
Of  these, 12 patients were excluded for the following 
reasons: (1) ARFI measurement failure due to a lesion 
that was smaller than the ROI and at an inaccessible loca-
tion (deeper than 8 cm) (n = 7) or (2) poor compliance or 
inability to hold their breath as required (n = 5). Finally, 
50 patients with valid ARFI measurements were enrolled. 
If  a patient had multiple liver masses, only one mass of  
interest was chosen.
This study was approved by the institutional review 
board at Severance Hospital in Seoul, South Korea, and 
conformed to the ethical guidelines of  the 1975 Declara-
tion of  Helsinki. Written informed consent was obtained 
from all participants.
Histological confirmation of the liver masses
We performed a targeted biopsy on masses when a 
confirmatory histological diagnosis was needed or the 
radiological diagnosis was not confirmative. Among the 
50 masses in our study, 37 (74.0%) received targeted bi-
opsy for histological confirmation. Masses that had any 
component of  cholangiocellular carcinomas (CCC) or 
combined HCC (CHCC) were classified as CCC and the 
others as HCC. 
Clinical diagnosis of the liver masses
A clinical diagnosis of  HCC was made according to the 
American Association for the Study of  Liver Disease 
recommendation[26]. Briefly, patients were diagnosed with 
HCC if  they had a tumor with a maximum diameter > 
2 cm and exhibited typical features of  HCC on dynamic 
CT, defined as enhancement in the arterial phase, early 
washout on the portal phase, and an α-fetoprotein level 
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> 200 ng/mL. Overall, nine patients satisfied these cri-
teria sufficiently to be diagnosed with HCC without a 
histological examination.
The presence of  a hemangioma was diagnosed clini-
cally in four patients, based on a combination of  typical 
findings, determined using CT or MRI, and a lack of  
growth for at least 12 mo[22]. A hemangioma appears as 
a mass with hypoattenuation on unenhanced CT, very 
high signal intensity on T2-weighted images, peripheral 
nodular enhancement in the arterial phase, and progres-
sive filling-in of  enhancement with no washout in later 
phases[20]. 
ARFI elastography
ARFI elastography was performed with an Acuson S2000 
ultrasound system (Siemens, Erlanger, Germany), using 
a 4-1 MHz curved array probe. ARFI elastography was 
performed by a single physician in all patients (2 years 
of  experience with US and more than 100 examinations 
with ARFI elastography) who was blinded with regard to 
the clinical and biochemical data. For patients who un-
derwent liver biopsy, ARFI elastography was performed 
just before the biopsy, on the same day. For patients with 
a solitary liver mass that was clinically diagnosed, ARFI 
elastography was performed at the time of  enrollment in 
this study.
Details of  the technical background and examination 
procedure have been described previously[27]. Briefly, a 
B-mode US image of  the lesion was identified utilizing a 
ROI, characterized by a box with a fixed dimension of  1 
cm × 0.5 cm and a maximum depth of  8 cm. The ROI 
was entirely located in the lesion, and the ROI location 
was changed to cover large masses as much as possible 
without including any vascular or biliary structures (Fig-
ure 1). The potential presence of  degeneration, such as 
necrotic, cystic, or calcified portions, was not included in 
the ROI. To evaluate background liver status of  the focal 
mass, measurements were also taken in the surrounding 
liver parenchyma with the ROI within 2-3 cm from the 
target mass, taking care not to comprise any vascular or 
biliary structure. To ensure quality of  the ARFI measure-
ment, 10 measurements were performed for each mass 
and surrounding liver parenchyma.
Statistical analysis
Continuous variables are expressed as medians and rang-
es. The χ 2 test or Fisher’s exact test and the Mann-Whit-
ney test were used to compare categorical and continuous 
variables, respectively. Receiver operating characteristics 
(ROC) curves and areas under the ROC curves (AU-
ROC) were used to estimate diagnostic performance. The 
cutoff  ARFI value for maximal diagnostic accuracy was 
selected by considering the highest sum of  sensitivity and 
specificity. A P-value < 0.05 was considered statistically 
significant. The statistical analysis was performed using 
SPSS software ver. 18.0.0 (Chicago, IL, United States). 
RESULTS
Final diagnosis of focal liver masses
We further excluded three masses that were non-
diagnostic on biopsy due to a lack of  sufficient tissue or 
ineffective targeting of  the mass. Thus, 47 masses (34 
histologically confirmed and 13 clinically diagnosed) were 
evaluated (Figure 2).
Overall, 15 HCCs, eight metastases (three from 
colorectal cancers, two from gallbladder cancer, one from 
pancreatic cancer, one from a gastrointestinal stromal 
tumor, and one from cervical cancer), seven CCCs, three 
focal nodular hyperplasias (FNH), and one hemangioma 
were diagnosed. Figure 3 describes pre-biopsy and post-
biopsy diagnoses: 21 (61.8%) masses were consistent 
with the pre-biopsy diagnosis, and 10 masses diagnosed 
as HCC or CHCC at the time of  pre-biopsy were finally 
confirmed as six HCCs and four CCCs through the bi-
opsy. The histological diagnosis of  the other three masses 
changed (two FNHs to one hemangioma and one HCC; 
one poorly-differentiated malignancy or metastatic mass 
to CCC).
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Figure 1  Measurement of acoustic radiation force impulse value within 
the region of interest of a focal liver mass. The shear wave velocity mea-
sured when the region of interest box was placed within the mass.
62 focal liver masses
50 masses with valid ARFI
13 masses with 
clinically diagnosis
37 masses with 
histological diagnosis 
47 masses were analyzed
(1) ARFI measurement failure (n  = 7)
(2) Patients’ poor compliance (n  = 5)
Non-diagnostic on biopsy (n  = 3)
Figure 2  Recruitment algorithm.
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P = 0.048), and the AUROC for discriminating HCCs 
from benign masses was 0.813 (95%CI, 0.649-0.976, P = 
0.008) (Table 2). To maximize the sum of  sensitivity and 
specificity, an ARFI value of  1.82 m/s was selected as the 
cutoff  value to differentiate malignant from benign liver 
masses. Furthermore, the cutoff  value for distinguishing 
HCCs from benign masses was also determined to be 1.82 
m/s (Table 2). Additionally, the diagnostic performance 
of  the sum of  the ARFI values for focal liver masses and 
the surrounding liver parenchyma to differentiate liver 
masses improved (AUROC = 0.853; 95%CI, 0.745-0.960; 
P = 0.002 in malignant liver masses vs benign ones and 
AUROC = 0.948; 95%CI, 0.896-0.992, P < 0.001 in 
HCCs vs benign masses) (Table 2). 
DISCUSSION
ARFI elastography has been proposed as a new method 
for assessing liver stiffness[7-9]. Although ARFI elastog-
raphy uses shear wave velocity (m/s) to assess liver stiff-
ness, which is similar to FibroScan®, it exhibits several 
unique properties. First, ARFI elastography allows for 
the evaluation of  deep tissue by generating a shear wave 
without the need for exertional compression[7,28]. Sec-
ond, ARFI elastography has the distinct advantage of  
being integrated into a conventional US system and can 
provide additional real-time information during a con-
ventional US study[14,15]. Third, ARFI elastography can be 
performed regardless of  the presence of  impediments 
such as ascites, although the reproducibility in this setting 
should be further investigated[19,29]. Finally, ARFI elastog-
raphy offers a flexible metering box at variable depths, 
allowing the examination of  specific liver areas[21,30]. Due 
to these characteristics, the clinical applicability of  ARFI 
elastography has expanded to characterize and distinguish 
focal liver masses beyond a simple assessment of  liver 
fibrosis[6,20-25].
According to previous studies[22,24,25], malignant liver 
masses are stiffer than benign masses, as reflected by high-
er ARFI values. Consistent with this finding, the ARFI 
values of  malignant liver masses (2.31 m/s) or HCCs (2.48 
m/s) in our cohort were significantly higher than those of  
benign masses (1.51 m/s) (all P < 0.05). However, when 
we consider that two types of  malignant liver masses 
(HCCs and CCCs) with different ARFI values were strati-
fied into one malignant mass group in our study, the ac-
curacy of  ARFI elastography for identifying malignant 
liver masses would change according to the proportion 
of  HCCs and CCCs. Thus, an exact comparison between 
the ARFI values of  HCCs and CCCs as well as those of  
benign masses should be performed in future, larger-scale 
studies. Additionally, the respective ARFI values of  HCCs 
and metastatic masses in our study were 2.48 m/s and 2.35 
m/s, which were similar to data from previous studies 
(2.45 to 2.63 m/s in HCC and 2.18 to 2.88 m/s in metas-
tasis)[22,23]. 
ARFI values for hemangiomas vary among re-
ports[6,20,22,23]. The ARFI values of  hemangiomas reported 
Characteristics and ARFI values of focal liver masses
The depth, location (right vs left lobe), and size of  each 
focal liver mass are described in Table 1. ARFI values of  
HCCs and metastases were higher (2.48 and 2.35 m/s) 
than those of  hemangiomas (1.83 m/s), CCCs (1.65 m/
s), and FNH (0.97 m/s). ARFI values for CCCs, hem-
angiomas, and metastases were significantly higher than 
those for their surrounding liver parenchyma (mean 1.65 
vs 1.07 m/s in CCCs; 1.83 m/s vs 1.10 m/s in hemangio-
mas; 2.35 m/s vs 1.45 m/s in metastases; all P < 0.05), 
whereas ARFI values for HCCs were similar to those of  
surrounding liver parenchyma (2.48 m/s vs 2.14 m/s, P = 
0.134).
When HCCs, CCCs, and metastases were categorized 
into a malignant liver mass group (n = 39) and the oth-
ers were stratified into a benign mass group (n = 8), a 
significant difference appeared in the between the malig-
nant and benign liver masses (2.31 ± 1.05 m/s vs 1.51 ± 
0.69 m/s, P = 0.047) (Figure 4A). However, considerable 
overlap in ARFI values was noted between malignant and 
benign masses. Additionally, a significant difference in the 
ARFI values was observed between the HCCs and the 
benign masses (2.48 ± 0.84 m/s vs 1.51 ± 0.69 m/s, P = 
0.006) (Figure 4A). To address this overlap, we attempted 
further analysis taking into consideration the ARFI values 
of  surrounding liver parenchyma as well as those of  focal 
liver masses. When ARFI values of  focal liver masses and 
their surrounding liver parenchyma were combined, the 
differences in ARFI values for each tumor type became 
more prominent (4.29 ± 1.22 m/s vs 2.92 ± 0.35 m/s for 
malignant masses vs benign masses, P < 0.001; 4.62 ± 0.96 
m/s vs 2.92 ± 0.35 m/s for HCCs vs benign masses, P < 
0.001) (Figure 4B).
Discrimination of malignant liver masses and HCCs 
from benign masses
The AUROC for discriminating the malignant masses 
from benign masses was 0.724 (95%CI, 0.566-0.883, 
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FNH (n  = 5)
Pre-biopsy diagnosis
HCC (n  = 8)
HCC or CHCC 
(n  = 10)
CCC (n  = 2)
Poorly differentiated 
tumor or metastases 
(n  = 9)
FNH (n  = 3)
Pre-biopsy diagnosis
Hemangioma (n  = 1)
HCC (n  = 15)
CCC (n  = 7)
Metastases (n  = 8)
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1
Figure 3  The flow of histological diagnosis. The values on arrows indicate 
the number of patients who obtained diagnoses differing from those pre-biopsy 
diagnoses after liver biopsy. 
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in two previous studies (1.51 and 1.75 m/s, respectively) 
were comparable to our data (1.83 m/s)[20,22,23], whereas 
the ARFI value for a hemangioma in another study was 
rather higher (2.36 m/s)[22,23]. The variability in hemangio-
ma ARFI values has been explained based on the amount 
of  fibrotic septa that divide the dilated vascular spaces[22]. 
That is, hemangiomas are composed of  multiple vascular 
channels filled with blood so they would not be expected 
to be stiff, and therefore would have low ARFI values; 
in contrast, those including pathological patterns such 
as sclerosis, thrombosis of  the vessels, or calcification, 
would be stiff  and have high ARFI values[20]. Because 
relatively few hemangioma cases were analyzed in these 
studies, this discrepancy will need to be investigated via 
further study including a larger number of  cases.
Some researchers have attempted to suggest a cutoff  
ARFI value for distinguishing malignant liver masses 
from benign masses. We obtained a high PPV (malignant 
masses vs benign masses, PPV 93.3%; HCC vs benign 
masses, 90.5%) using the cutoff  ARFI value of  1.82 m/s, 
which maximized the sum of  the sensitivity and specific-
ity for distinguishing masses. Our cutoff  value of  1.82 
m/s for identifying malignant liver masses was slightly 
lower than those in previous studies (2.0 to 2.5 m/s)[22,24,25], 
Table 1  Characteristics and acoustic radiation force impulse values of focal liver masses
Variables Total masses (n  = 47) HCC (n  = 24) CCC (n  = 7) Metastases (n  = 8) Hemangioma (n  = 5) FNH (n  = 3)
Histologic confirmation 34 (72.3) 15 (62.5) 7 (100) 8 (100) 1 (20.0) 3 (100)
Size, cm      5.0 (1.4-20.5)      4.9 (1.4-18.3)     9.4 (7.4-18.8)     8.0 (1.6-20.5)  1.9 (1.5-4.7)   2.7 (2.0-3.0)
Depth, cm    5.6 (2.7-7.8)    5.7 (2.7-7.8)   6.4 (4.8-7.2)   4.9 (3.5-7.6)  5.3 (4.5-6.5)   5.6 (2.8-7.8)
Right/left lobe 34 (72.3)/13 (27.7) 19 (79.2)/5 (20.8) 5 (71.4)/2 (28.6) 5 (62.5)/3 (37.5) 4 (80.0)/1 (20.0) 1 (33.3)/2 (66.7)
ARFI value, m/s
   Masses 2.23 ± 0.98 2.48 ± 0.84 1.65 ± 1.43 2.35 ± 1.18 1.83 ± 0.62 0.97 ± 0.48
   Surrounding parenchyma 1.83 ± 0.73 2.14 ± 0.59 1.07 ± 0.49 1.45 ± 0.51 1.10 ± 0.14 1.63 ± 0.40
   P value 0.029 0.134 0.015 0.043 0.013 0.581
Data was expressed as median (range) or n (%). HCC: Hepatocellular carcinoma; CCC: Cholangiocellular carcinoma; FNH: Focal nodular hyperplasia; 
ARFI: Acoustic radiation force impulse.
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Figure 4  Acoustic radiation force impulse values of malignant masses, hepatocellular carcinoma, and benign masses. A: Acoustic radiation force impulse 
(AFRI) value of a focal liver mass; B: Sum of the ARFI values of liver mass and the surrounding liver parenchyma. HCC: Hepatocellular carcinoma.
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Table 2  Optimal cutoff acoustic radiation force impulse values and corresponding diagnostic indices for discriminating malignant 
masses and hepatocellular carcinoma from benign liver masses
Malignant vs  benign HCC vs  benign
Masses Masses with surrounding liver parenchyma Masses Masses with surrounding liver parenchyma
Cutoff ARFI value, m/s       1.821           3.722       1.821           3.792
AUROC (95%CI) 0.724 (0.566-0.883) 0.853 (0.745-0.960) 0.813 (0.649-0.976) 0.948 (0.896-0.992)
Sensitivity, % 71.8      71.8 79.2      87.5
Specificity, % 75.0 100 75.0 100
Positive predictive value, % 93.3 100 90.5 100
Negative predictive value, % 35.3      42.1 54.5      72.9
1ARFI value of a focal liver mass; 2Sum of ARFI values of focal liver mass and surrounding liver parenchyma. ARFI: Acoustic radiation force impulse; HCC: 
Hepatocellular carcinoma; AUROC: Area under the receiver operating characteristics; CI: Confidence intervals.
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which can be partially explained by the different meth-
ods used to categorize the masses. In one study, which 
reported a rather high cutoff  value of  2.5 m/s, only 
metastases that had a high ARFI value of  4.18 m/s were 
categorized into a malignant group and compared with 
benign masses[24], whereas another study that reported 
2.22 m/s as a cutoff  value for discriminating malignant 
masses from benign masses included FNHs, adenomas, 
and focal fatty change lesions in the benign mass group 
as well as hemangiomas[25]. Thus, in this regard, further 
study is needed to prevent potential bias due to hetero-
geneity of  the masses and to confirm the clinically appli-
cable cutoff  values for ARFI elastography. Although our 
cutoff  value may be useful to physicians who encounter 
focal liver masses during routine US evaluation, it should 
be interpreted cautiously in the clinical context for several 
reasons. First, although our cutoff  value would correctly 
characterize HCC and metastasis, it would mischaracter-
ize CCC with a relatively low ARFI value and hemangio-
ma with a relatively high ARFI value. Second, there was 
considerable overlap of  ARFI values between malignant 
and benign masses. 
Underlying fibrosis of  the liver is a consideration for 
the differential diagnosis of  a focal liver mass. Several 
previous studies have proposed that HCCs generally ap-
pear softer (lower ARFI values) than the surrounding 
liver[21], whereas metastases and hemangiomas generally 
appear harder than that of  the surrounding liver despite 
some controversies among studies[21]. Similarly, we found 
that CCCs, hemangiomas, and metastases had higher 
ARFI values than those of  surrounding liver paren-
chyma, whereas ARFI values of  HCCs were statistically 
equivalent to those of  the surrounding liver parenchyma. 
Because hemangiomas and metastases were evaluated in 
patients without chronic liver disease in most studies[6,25], 
ARFI values seemed consistently higher than those of  a 
background liver. In contrast, because HCCs were evalu-
ated in patients with chronic liver disease and diverse de-
grees of  background liver fibrosis, the comparative results 
between ARFI values of  HCCs and those of  background 
liver differed among studies based on the characteristics 
of  each study cohort[6,21,25]. That is, simultaneously mea-
suring ARFI values of  focal liver mass and the surround-
ing liver should focus on assessing the respective char-
acteristics of  the hepatic mass and surrounding fibrosis 
to prevent a misdiagnosis of  the hepatic mass using the 
correlation of  ARFI values between the liver mass and 
background liver parenchyma. However, when we used 
the sum of  ARFI values of  focal liver mass and the sur-
rounding liver parenchyma, the diagnostic performance 
in terms of  distinguishing liver mass improved. Thus, 
these controversial findings concerning the simultane-
ous measurement of  liver masses and their surrounding 
liver parenchyma should be further investigated in future 
larger-scale studies.
Although most cases (72.3%) were histologically con-
firmed in our study, the relative small sample size of  our 
cohort and inclusion of  patients with high ALT, which 
has the potential of  overestimating influences on ARFI 
values[30,31], are potential limitations. Although ARFI elas-
tography can freely locate the ROI box in a specific area 
within a mass and measure its stiffness, morphological 
characteristics of  liver masses including heterogeneous 
components such as HCC with hemorrhage and fatty 
metamorphosis[6,20,32] and lesion shapes were not consid-
ered in our study, which is a limitation of  this study. Fur-
ther investigation of  how to evaluate such heterogeneous 
or morphologically varying liver masses using ARFI 
elastography and their influences on ARFI values of  liver 
masses should be conducted.
In our study, we demonstrated the potential clinical 
utility of  ARFI elastography for characterization of  fo-
cal liver masses. Although this study had limitations and 
should be interpreted cautiously, our findings provide a 
useful reference for the differential diagnosis of  a focal 
liver mass and will provide additional information to cli-
nicians who are confronted with a need for an immediate 
diagnosis of  a focal liver mass during a routine US ex-
amination before a further diagnostic imaging study such 
as contrast-enhanced US, CT or MRI. However, further 
studies with larger numbers of  cases are warranted to as-
sess the utility of  ARFI elastography in the clinic.
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Terminology
ARFI elastography is an emerging examination which can quantify tissue elas-
ticity. ARFI elastography has the distinct advantage of being integrated into a 
conventional US system and can be checked simultaneously during a conven-
tional US study. Furthermore, because ARFI elastography uses elastography 
with a flexible metering box of the region of the interest, it is suitable for quanti-
fying focal liver mass stiffness.
Peer review
Although this study had limitations and should be interpreted cautiously, their 
results show the clinical applicability of ARFI elastography as a complementary 
diagnostic tool for the differential diagnosis of liver masses.
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